John Docherty
John Docherty, M. Sc., is president and chief operating officer at Helix BioPharma.
Articles
Stabilization of Interferon alpha-2b in a Topical Cream
Kim Gaspar;Jinghui Shen;John Docherty;Ravinderjit Batta;Geriene LaBine;Praveen Kumar;Marianna Foldvari
July 2nd 2009The authors describe a proprietary process for producing a stable, topical interferon alpha-2b formulation that can deliver large drug molecules into the skin or mucosa.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: November 6th 2024 | Updated: November 20th 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 20th 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 20th 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
Published: November 4th 2024 | Updated: November 20th 2024
Strategies for Overcoming Common Challenges in Tech Transfer
